Clinical Trial Detail

NCT ID NCT04032704
Title A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seattle Genetics, Inc.
Indications

esophagus squamous cell carcinoma

lung non-small cell carcinoma

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

lung small cell carcinoma

Therapies

Ladiratuzumab vedotin

Age Groups: senior adult

No variant requirements are available.